Rob Davis, Merck CEO (Jeenah Moon/Bloomberg via Getty Images)
May 29, 2024 06:34 AM EDTUpdated 07:53 AM
Startups
Deals
Pharma

Mer­ck re­turns to lu­cra­tive eye dis­ease mar­ket in up to $3B deal for Eye­Bio

Kyle LaHucik

Senior Reporter

A decade af­ter de­part­ing the oph­thal­mol­o­gy drug mar­ket, Mer­ck is launch­ing a re­turn to the field in a $1.3 bil­lion up­front cash ac­qui­si­tion for Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times